- Home
- API vs CAPR Comparison
API vs CAPR Comparison
Compare API & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- API
- CAPR
- Stock Information
- Founded
- API 2013
- CAPR 2005
- Country
- API United States
- CAPR United States
- Employees
- API N/A
- CAPR N/A
- Industry
- API Computer Software: Prepackaged Software
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- API Technology
- CAPR Health Care
- Exchange
- API Nasdaq
- CAPR Nasdaq
- Market Cap
- API 315.7M
- CAPR 324.6M
- IPO Year
- API 2020
- CAPR N/A
- Fundamental
- Price
- API $3.40
- CAPR $5.60
- Analyst Decision
- API Strong Buy
- CAPR Strong Buy
- Analyst Count
- API 1
- CAPR 6
- Target Price
- API $6.00
- CAPR $23.17
- AVG Volume (30 Days)
- API 317.6K
- CAPR 1.5M
- Earning Date
- API 11-19-2025
- CAPR 11-10-2025
- Dividend Yield
- API N/A
- CAPR N/A
- EPS Growth
- API N/A
- CAPR N/A
- EPS
- API N/A
- CAPR N/A
- Revenue
- API $133,554,000.00
- CAPR $11,130,509.00
- Revenue This Year
- API $7.20
- CAPR N/A
- Revenue Next Year
- API $11.26
- CAPR $7,894.07
- P/E Ratio
- API N/A
- CAPR N/A
- Revenue Growth
- API N/A
- CAPR N/A
- 52 Week Low
- API $2.53
- CAPR $5.43
- 52 Week High
- API $6.99
- CAPR $20.75
- Technical
- Relative Strength Index (RSI)
- API 40.88
- CAPR 40.44
- Support Level
- API $3.45
- CAPR $5.43
- Resistance Level
- API $3.76
- CAPR $6.54
- Average True Range (ATR)
- API 0.12
- CAPR 0.48
- MACD
- API -0.00
- CAPR -0.04
- Stochastic Oscillator
- API 32.86
- CAPR 9.09
About API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.